Vaderis Therapeutics

Vaderis Therapeutics announced $152M in Series B financing on August 11, 2026. Vaderis Therapeutics closed a $152 million Series B co-led by Life Sciences at Goldman Sachs Alternatives and TCGX as it began the Phase 3 HEROIC study of engasertib in HHT.

Round details

The financing includes backing from Life Sciences at Goldman Sachs Alternatives, TCGX, Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, Medicxi, Droia. The company did not publish a valuation with the announcement.

• Round: Series B
• Capital announced: $152M
• Headquarters: Basel, Switzerland

How the company plans to use the capital

Vaderis said the proceeds are expected to fund its planned operations through regulatory submissions and potential U.S. regulatory approval. The financing was announced alongside the start of the global Phase 3 HEROIC study of oral engasertib in moderate-to-severe hereditary hemorrhagic telangiectasia.

Why this matters for GTM teams

Vaderis said hereditary hemorrhagic telangiectasia currently has no approved therapies globally, and that engasertib has not been approved for use in any country for any indication.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Vaderis Therapeutics Series B announcement.